Product analysis
Flush-Free Niacin 500 mg offers an explicitly identified niacin preparation, making it easier to distinguish from other forms. Its connection to cardiovascular support remains uncertain for this particular preparation.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality70
The niacin preparation is clearly identified, avoiding ambiguity about which form is included. The inositol preparation is named, but its quality cannot be confirmed.
Ingredient Transparency100
Amounts and preparations are disclosed for both listed ingredients. That makes it easier to compare the contents with other niacin supplements.
Value For Money60
The identified niacin preparation offers moderate value for the serving cost. The added inositol does not establish a further value advantage.
Customer Satisfaction72
Customer feedback is very positive, though based on a relatively small pool of ratings. That limits confidence about how widely satisfaction is shared.
Product Focus0
A cardiovascular benefit cannot be established for this inositol-bound niacin preparation. That uncertainty does not prove ineffectiveness, but it limits the basis for choosing it for that purpose.
- Format
Capsule - Container
- 120 Capsule(s)
- Per serving
- $0.25
- Customer rating
- 4.7 · 118 ratings
Goals
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Niacin (Inositol Hexaniacinate) | 500 mg | |
Inositol (Inositol Hexanicotinate) | 88 mg |
How this ingredient is rated
Active Ingredient Quality & Bioavailability64
Niacin Form & Goal Alignment
Precursor Source Quality
Dose, Safety & Label Transparency75
Clarity of Chemical Form
Form-Specific Dosage Efficacy
Flush Risk & Safety Labeling
Value60
Price Per Effective Serving
Alternative products
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
- Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
- Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
- Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
- Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
- Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
- The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
- The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
- Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
- Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.